A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Status Completed

Clinical Trial Summary

This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase 3 study, as well as, new participants who were unable to participate in the Phase 3 study, who meet all enrollment criteria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

DEB - Dystrophic Epidermolysis Bullosa
Dominant Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa
Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica
Recessive Dystrophic Epidermolysis Bullosa

Clinical Trial Details

NCT number	NCT04917874
Study type	Interventional
Source	Krystal Biotech, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	May 25, 2021
Completion date	July 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02493816` - Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa	Phase 1
Completed	`NCT04599881` - A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa	Phase 2
Completed	`NCT04520022` - Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB	Phase 1/Phase 2
Not yet recruiting	`NCT03632265` - Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa	Phase 3
Recruiting	`NCT05944250` - A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients	N/A
Recruiting	`NCT04917887` - Long-Term Follow-up Protocol
Not yet recruiting	`NCT04285294` - Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
Active, not recruiting	`NCT04213261` - A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa	Phase 3
Active, not recruiting	`NCT02323789` - Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa	Phase 1/Phase 2
Recruiting	`NCT01874769` - Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)	N/A
Recruiting	`NCT03392909` - Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Phase 1/Phase 2
Completed	`NCT03752905` - A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Phase 1/Phase 2
Terminated	`NCT02984085` - Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.	Phase 1/Phase 2
Completed	`NCT04227106` - Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Phase 3
Completed	`NCT02698735` - Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients	Phase 1/Phase 2
Completed	`NCT03012191` - Gentamicin for RDEB	Phase 1/Phase 2
Completed	`NCT03529877` - Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa	Phase 1/Phase 2
Completed	`NCT05143190` - Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)	Phase 2
Recruiting	`NCT04177498` - Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC	Early Phase 1
Completed	`NCT04491604` - Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB	Phase 3